Cencora, Inc. · NYSE:COR
Cencora — AmerisourceBergen — Q4 FY2018 Earnings Presentation
17 slides from Cencora's earnings presentation, Nov 6, 2018
Slide 1: Q4 & Full Year FY2018 Financial Results
Q4 & Full Year FY2018 Financial Results November 6, 2018
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements Certain of the statements contained in this presentation are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Words such as “expect,” “likely,” “ou
Slide 3: AmerisourceBergen is creating healthier futures
AmerisourceBergen is creating healthier futures Driving innovative partnerships with global manufacturers, providers and pharmacies to improve product access and efficiency throughout the healthcare supply chain 3
Slide 4: Q4 and Full Year FY2018 Financial Results: Overview
Q4 and Full Year FY2018 Financial Results: Overview • Strong year-over-year revenue and EPS growth AmerisourceBergen • Deepened and expanded customer relationships continues to execute and • Continued to lead the market in Specialty distribution and deliver in a dynamic services environment • Delive
Slide 5: Q4 FY2018 Financial Results
Q4 FY2018 Financial Results Adjusted GAAP (Non-GAAP)1 Revenue $43.3B $43.3B % Change (Year-over-Year) 10.7% 10.7% Gross Profit $1.0B $1.2B % Change (11.9)% 6.2% Operating Expenses $879M $732M % Change (32.8)% 17.0% Operating Income $154M $432M % Change 214.1% (8.2)% Interest Expense, Net $43M $43M %
Slide 6: Full Year FY2018 Financial Results
Full Year FY2018 Financial Results Adjusted GAAP (Non-GAAP)1 Revenue $167.9B $167.9B % Change (Year-over-Year) 9.7% 9.7% Gross Profit $4.6B $4.7B % Change 1.5% 7.8% Operating Expenses $3.2B $2.7B % Change (9.1)% 15.9% Operating Income $1.4B $2.0B % Change 36.2% (1.8)% Interest Expense, Net $175M $17
Slide 7: Q4 FY2018 Pharmaceutical Distribution Services Segment
Q4 FY2018 Financial Results: Pharmaceutical Distribution Services Segment Q4 FY2018 Q4 FY2017 Revenue $41.7B $37.7B Operating Income $356.8M $399.7M Percentages of Revenue Gross Profit 2.06% 2.14% Operating Expenses 1.21% 1.07% Operating Income 0.86% 1.06% Large anchor customers continue to grow
Slide 8: Other Businesses – Global Commercialization Services & Animal Health
Q4 FY2018 Financial Results: Other Businesses – Global Commercialization Services & Animal Health Q4 FY2018 Q4 FY2017 Revenue $1.6B $1.5B Operating Income $75.5M $71.7M Percentages of Revenue Gross Profit 19.02% 19.82% Operating Expenses 14.29% 14.97% Operating Income 4.73% 4.85% Other includes Wo
Slide 9: How AmerisourceBergen Will Continue to Drive Value
How AmerisourceBergen Will Continue to Drive Value Customer Base Innovative Services & • Key anchor customers Solutions • Fast growing • Customer-focused offerings serving • U.S. Pharmaceutical focus manufacturers and provider customers Leadership in Specialty Successful Financial Distribution & Ser
Slide 10: FY19 Financial Guidance
FY19 Financial Guidance Expectations on an Adjusted (Non-GAAP) Basis (1) Revenue Mid-single digit percent growth Diluted Earnings Per Share $6.65 to $6.95 Operating Expense Mid-single digit percent growth Low-single to mid-single digit Operating Income percent growth Pharmaceutical Distribution Serv
Slide 11: Appendix
Appendix N) AmerisourceBergen’
Slide 12: Appendix
Appendix Note: For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of the Company’s most recent Current Report on Form 8-K furnished under Item 2.02. 12
Slide 13: Appendix
Appendix Note: For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of the Company’s most recent Current Report on Form 8-K furnished under Item 2.02. 13
Slide 14: Appendix
Appendix Note: For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of the Company’s most recent Current Report on Form 8-K furnished under Item 2.02. 14
Slide 15: Appendix
Appendix Note: For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of the Company’s most recent Current Report on Form 8-K furnished under Item 2.02. 15
Slide 16: Appendix
Appendix Note: For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of the Company’s most recent Current Report on Form 8-K furnished under Item 2.02. 16
Slide 17: AmerisourceBergen
N) AmerisourceBergen’ Where knowledge, reach and partnership shape healthcare delivery.